Log on / register
BioMed Central home | Journals A-Z | Feedback | Support | My details
Open AccessResearch

Time course of angiopoietin-2 release during experimental human endotoxemia and sepsis

Philipp Kümpers* 1 email, Matijs van Meurs* 2,3 email, Sascha David1 email, Grietje Molema3 email, Johan Bijzet3 email, Alexander Lukasz1 email, Frank Biertz4 email, Hermann Haller1 email and Jan G Zijlstra2 email

1Department of Nephrology & Hypertension, Hannover Medical School, Carl-Neuberg-Straße 1, 30625 Hannover, Germany

2Department of Critical Care, University Medical Center Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands

3Department of Pathology and Medical Biology, University Medical Center Groningen, Hanzeplein 19713 GZ Groningen, The Netherlands

4Department of Biometrics, Hannover Medical School, Carl-Neuberg-Straße 1, 30625 Hannover, Germany

author email corresponding author email* Contributed equally

Critical Care 2009, 13:R64doi:10.1186/cc7866

Published: 5 May 2009

Abstract

Introduction

Endothelial activation leading to vascular barrier breakdown denotes a devastating event in sepsis. Angiopoietin (Ang)-2, a circulating antagonistic ligand of the endothelial specific Tie2 receptor, is rapidly released from Weibel-Palade and has been identified as a non-redundant gatekeeper of endothelial activation. We aimed to study: the time course of Ang-2 release during human experimental endotoxemia; the association of Ang-2 with soluble adhesion molecules and inflammatory cytokines; and the early time course of Ang-2 release during sepsis in critically ill patients.

Methods

In 22 healthy volunteers during a 24-hour period after a single intravenous injection of lipopolysaccharide (LPS; 4 ng/kg) the following measurement were taken by immuno luminometric assay (ILMA), ELISA, and bead-based multiplex technology: circulating Ang-1, Ang-2, soluble Tie2 receptor, the inflammatory molecules TNF-alpha, IL-6, IL-8 and C-reactive protein, and the soluble endothelial adhesion molecules inter-cellular adhesion molecule-1 (ICAM-1), E-selectin, and P-selectin. A single oral dose of placebo or the p38 mitogen activated protein (MAP) kinase inhibitor drug, RWJ-67657, was administered 30 minutes before the endotoxin infusion. In addition, the course of circulating Ang-2 was analyzed in 21 septic patients at intensive care unit (ICU) admission and after 24 and 72 hours, respectively.

Results

During endotoxemia, circulating Ang-2 levels were significantly elevated, reaching peak levels 4.5 hours after LPS infusion. Ang-2 exhibited a kinetic profile similar to early pro-inflammatory cytokines TNF-alpha, IL-6, and IL-8. Ang-2 levels peaked prior to soluble endothelial-specific adhesion molecules. Finally, Ang-2 correlated with TNF-alpha levels (r = 0.61, P = 0.003), soluble E-selectin levels (r = 0.64, P < 0.002), and the heart rate/mean arterial pressure index (r = 0.75, P < 0.0001). In septic patients, Ang-2 increased in non-survivors only, and was significantly higher compared with survivors at baseline, 24 hours, and 72 hours.

Conclusions

LPS is a triggering factor for Ang-2 release in men. Circulating Ang-2 appears in the systemic circulation during experimental human endotoxemia in a distinctive temporal sequence and correlates with TNF-alpha and E-selectin levels. In addition, not only higher baseline Ang-2 concentrations, but also a persistent increase in Ang-2 during the early course identifies septic patients with unfavorable outcome.


© 1999-2009 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.